Quick Takeaways
- DTIL - PRECISION BIOSCIENCES INC has 19 insiders with reported activity on this page.
- Net insider value flow over the last year: -$447,272.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 19 Insiders of PRECISION BIOSCIENCES INC
- Symbol
- DTIL on Nasdaq
- Location
- Durham, NC
What Changed
- Buy value: $82,058; sell value: $529,330.
- Net share flow: -109,889.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$447,272.
Buys
$82,058
Shares: 17,939
Insiders: 4
Sells
$529,330
Shares: 127,828
Insiders: 4
Net
-$447,272
Shares: -109,889
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 38,558 | $0 | $148,063 | -$148,063 |
| 3-6 | 7,081 | 74,443 | $33,714 | $318,105 | -$284,391 |
| 6-9 | 4,100 | 0 | $20,265 | $0 | +$20,265 |
| 9-12 | 6,758 | 14,827 | $28,080 | $63,163 | -$35,083 |
PRECISION BIOSCIENCES INC executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| NOVARTIS PHARMA AG | 10%+ Owner | $4,590,753 | Mixed | 15 Jun 2022 | ||
| Derek Jantz | Chief Scientific Officer, Director | $1,509,439 | Mixed | 07 Jun 2022 | ||
| Michael Amoroso | President and CEO, Director | $934,625 | -$246,183 | -21% | Filing P/S | 17 Feb 2026 |
| Matthew R. Kane | President and CEO, Director | $749,324 | Mixed | 07 Jun 2021 | ||
| J. Jefferson Smith | Chief Research Officer | $500,236 | -$60,018 | -11% | Mixed | 17 Feb 2026 |
| John Alexander Kelly | Chief Financial Officer | $483,390 | -$164,220 | -25% | Filing P/S | 17 Feb 2026 |
| Kevin Buehler | Director | $234,961 | +$21,116 | +9.9% | Mixed | 25 Jun 2025 |
| Melinda Brown | Director | $233,941 | +$20,673 | +9.7% | Mixed | 15 Dec 2025 |
| Geno J. Germano | Director | $230,639 | +$14,160 | +6.5% | Mixed | 16 Dec 2025 |
| Dario Scimeca | General Counsel and Secretary | $216,794 | -$58,909 | -21% | Filing P/S | 17 Feb 2026 |
| Stanley R. Frankel | Director | $209,458 | +$26,109 | +14% | Mixed | 16 Dec 2025 |
| Shari Lisa Pire | Director | $189,875 | Mixed | 27 May 2025 | ||
| Samuel C. Wadsworth | Director | $161,277 | Mixed | 04 Jun 2024 | ||
| Alan List | Chief Medical Officer | $56,440 | Mixed | 01 May 2024 | ||
| David S. Thomson | Chief Operating Officer | $41,260 | Mixed | 23 Jun 2021 | ||
| Shane Barton | VP & Corporate Controller | $12,418 | Mixed | 07 Jun 2023 | ||
| Fayaz Khazi | CEO of Elo Life Systems | $8,880 | Mixed | 07 Jun 2021 | ||
| Shalini Sharp | Director | Mixed | 10 May 2021 | |||
| Raymond F. Schinazi | Director | Mixed | 10 May 2022 |
Top shareholders of PRECISION BIOSCIENCES INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Empery Asset Management, LP |
13D/G
13F
|
Company |
7.6%
|
1,968,879
|
$10,828,834 | -$1,808,961 | 31 Mar 2026 | |
| Octagon Capital Advisors LP |
13D/G
13F
|
Company |
10%
|
2,328,485
|
$9,570,073 | $0 | 31 Dec 2025 | |
| Aberdeen Group plc |
13D/G
13F
|
Company |
8.9%
|
2,138,603
|
$8,896,588 | $0 | 31 Dec 2025 | |
| Bleichroeder LP |
13D/G
13F
|
Company |
8.2%
|
1,900,000
|
$7,809,000 | +$3,390,750 | 31 Dec 2025 | |
| Readout Capital, LP |
13D/G
|
Matthew Smith |
9.4%
|
1,119,311
|
$4,980,934 | +$829,645 | 30 Jun 2025 | |
| NOVARTIS PHARMA AG |
3/4/5
13D/G
|
10%+ Owner |
3.7%
from 13D/G
|
12,407,440
|
$4,590,753 | — | 15 Jun 2022 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
4.1%
|
1,066,050
|
$4,434,768 | — | 31 Dec 2025 | |
| Lynx1 Capital Management LP |
13F
13D/G
|
Company |
4.1%
from 13D/G
|
993,913
|
$4,134,678 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.5%
|
906,782
|
$3,772,213 | — | 31 Dec 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
3.1%
|
798,000
|
$3,319,680 | — | 31 Dec 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
3.1%
|
787,700
|
$3,276,832 | — | 31 Dec 2025 | |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC |
13D/G
|
— |
3.7%
|
406,250
|
$2,165,312 | $0 | 31 Mar 2025 | |
| Weinstein Benjamin |
13D/G
|
— |
5.2%
|
395,489
|
$2,107,956 | $0 | 18 Mar 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
1.5%
|
396,116
|
$1,647,843 | — | 31 Dec 2025 | |
| Derek Jantz |
3/4/5
|
Chief Scientific Officer, Director |
—
mixed-class rows
|
4,079,565
mixed-class rows
|
$1,509,439 | — | 07 Jun 2022 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.3%
|
326,477
|
$1,358,144 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.87%
|
225,657
|
$938,763 | — | 31 Dec 2025 | |
| Michael Amoroso |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
378,985
mixed-class rows
|
$934,625 | -$246,183 | 17 Feb 2026 | |
| Matthew R. Kane |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
2,026,513
mixed-class rows
|
$749,324 | — | 07 Jun 2021 | |
| BlackRock, Inc. |
13F
|
Company |
0.65%
|
168,331
|
$700,256 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.54%
|
139,531
|
$580,449 | — | 31 Dec 2025 | |
| J. Jefferson Smith |
3/4/5
|
Chief Research Officer |
—
mixed-class rows
|
163,190
mixed-class rows
|
$500,236 | -$60,018 | 17 Feb 2026 | |
| John Alexander Kelly |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
181,049
mixed-class rows
|
$483,390 | -$164,220 | 17 Feb 2026 | |
| MORGAN STANLEY |
13F
|
Company |
0.39%
|
99,805
|
$415,189 | — | 31 Dec 2025 | |
| 683 Capital Management, LLC |
13F
|
Company |
0.38%
|
97,085
|
$403,874 | — | 31 Dec 2025 | |
| COMMONWEALTH EQUITY SERVICES, LLC |
13F
|
Company |
0.36%
|
93,306
|
$388,150 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.34%
|
86,464
|
$359,690 | — | 31 Dec 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.32%
|
83,443
|
$347,123 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.27%
|
70,915
|
$295,004 | — | 31 Dec 2025 | |
| Quarry LP |
13F
|
Company |
0.26%
|
68,311
|
$284,174 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.26%
|
66,581
|
$276,977 | — | 31 Dec 2025 | |
| Quadrature Capital Ltd |
13F
|
Company |
0.24%
|
62,129
|
$258,457 | — | 31 Dec 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.24%
|
61,901
|
$257,508 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.24%
|
61,332
|
$255,141 | — | 31 Dec 2025 | |
| OMERS ADMINISTRATION Corp |
13F
|
Company |
0.24%
|
60,700
|
$252,512 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.23%
|
59,042
|
$245,615 | — | 31 Dec 2025 | |
| Kevin Buehler |
3/4/5
|
Director |
—
mixed-class rows
|
49,137
mixed-class rows
|
$234,961 | +$21,116 | 25 Jun 2025 | |
| Melinda Brown |
3/4/5
|
Director |
—
mixed-class rows
|
44,346
mixed-class rows
|
$233,941 | +$20,673 | 15 Dec 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.22%
|
56,315
|
$233,000 | — | 31 Dec 2025 | |
| Geno J. Germano |
3/4/5
|
Director |
—
mixed-class rows
|
44,883
mixed-class rows
|
$230,639 | +$14,160 | 16 Dec 2025 | |
| Dario Scimeca |
3/4/5
|
General Counsel and Secretary |
—
mixed-class rows
|
89,790
mixed-class rows
|
$216,794 | -$58,909 | 17 Feb 2026 | |
| Stanley R. Frankel |
3/4/5
|
Director |
—
mixed-class rows
|
40,478
mixed-class rows
|
$209,458 | +$26,109 | 16 Dec 2025 | |
| Shari Lisa Pire |
3/4/5
|
Director |
—
mixed-class rows
|
35,028
mixed-class rows
|
$189,875 | — | 27 May 2025 | |
| Trexquant Investment LP |
13F
|
Company |
0.16%
|
40,256
|
$167,465 | — | 31 Dec 2025 | |
| Samuel C. Wadsworth |
3/4/5
|
Director |
—
mixed-class rows
|
14,028
mixed-class rows
|
$161,277 | — | 04 Jun 2024 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.15%
|
38,767
|
$161,000 | — | 31 Dec 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.14%
|
35,929
|
$149,465 | — | 31 Dec 2025 | |
| Jump Financial, LLC |
13F
|
Company |
0.14%
|
35,790
|
$148,886 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.11%
|
29,607
|
$123,165 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.09%
|
23,757
|
$98,829 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for PRECISION BIOSCIENCES INC
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Michael Amoroso | DTIL | Common Stock | Sale | -7.79% | $78,947 | $3.84 | -20,559 | 243,392 | 18 Feb 2026 | Direct |
| John Alexander Kelly | DTIL | Common Stock | Sale | -6.08% | $31,292 | $3.84 | -8,149 | 125,883 | 18 Feb 2026 | Direct |
| Dario Scimeca | DTIL | Common Stock | Sale | -8.02% | $18,912 | $3.84 | -4,925 | 56,457 | 18 Feb 2026 | Direct |
| J. Jefferson Smith | DTIL | Common Stock | Sale | -3.88% | $18,912 | $3.84 | -4,925 | 121,926 | 18 Feb 2026 | Direct |
| Michael Amoroso | DTIL | Common Stock | Options Exercise | 34.6% | 67,797 | 263,951 | 17 Feb 2026 | Direct | ||
| Michael Amoroso | DTIL | Restricted Stock Units | Options Exercise | -33.3% | -67,797 | 135,593 | 17 Feb 2026 | Direct | ||
| John Alexander Kelly | DTIL | Common Stock | Options Exercise | 25.9% | 27,584 | 134,032 | 17 Feb 2026 | Direct | ||
| John Alexander Kelly | DTIL | Restricted Stock Units | Options Exercise | -33.3% | -27,584 | 55,166 | 17 Feb 2026 | Direct | ||
| Dario Scimeca | DTIL | Common Stock | Options Exercise | 37.3% | 16,667 | 61,382 | 17 Feb 2026 | Direct | ||
| Dario Scimeca | DTIL | Restricted Stock Units | Options Exercise | -33.3% | -16,667 | 33,333 | 17 Feb 2026 | Direct | ||
| J. Jefferson Smith | DTIL | Common Stock | Options Exercise | 15.1% | 16,667 | 126,851 | 17 Feb 2026 | Direct | ||
| J. Jefferson Smith | DTIL | Restricted Stock Units | Options Exercise | -33.3% | -16,667 | 33,333 | 17 Feb 2026 | Direct | ||
| Michael Amoroso | DTIL | Common Stock | Sale | -15.1% | $145,112 | $4.17 | -34,799 | 196,154 | 22 Jan 2026 | Direct |
| Dario Scimeca | DTIL | Common Stock | Sale | -16.5% | $35,682 | $4.03 | -8,854 | 44,715 | 21 Jan 2026 | Direct |
| John Alexander Kelly | DTIL | Common Stock | Sale | -12.5% | $61,308 | $4.03 | -15,213 | 106,448 | 21 Jan 2026 | Direct |
| J. Jefferson Smith | DTIL | Common Stock | Sale | -8.47% | $41,106 | $4.03 | -10,200 | 110,184 | 21 Jan 2026 | Direct |
| J. Jefferson Smith | DTIL | Common Stock | Options Exercise | 15.6% | 16,219 | 120,384 | 21 Jan 2026 | Direct | ||
| Michael Amoroso | DTIL | Common Stock | Options Exercise | 99.8% | 115,378 | 230,953 | 20 Jan 2026 | Direct | ||
| Michael Amoroso | DTIL | Restricted Stock Units | Options Exercise | -100% | -115,378 | 0 | 20 Jan 2026 | Direct | ||
| Dario Scimeca | DTIL | Common Stock | Options Exercise | 89.6% | 25,311 | 53,569 | 20 Jan 2026 | Direct | ||
| Dario Scimeca | DTIL | Restricted Stock Units | Options Exercise | -100% | -25,311 | 0 | 20 Jan 2026 | Direct | ||
| John Alexander Kelly | DTIL | Common Stock | Options Exercise | 57.4% | 44,363 | 121,661 | 20 Jan 2026 | Direct | ||
| John Alexander Kelly | DTIL | Restricted Stock Units | Options Exercise | -100% | -44,363 | 0 | 20 Jan 2026 | Direct | ||
| J. Jefferson Smith | DTIL | Common Stock | Options Exercise | 14.2% | 12,947 | 104,165 | 20 Jan 2026 | Direct | ||
| J. Jefferson Smith | DTIL | Restricted Stock Units | Options Exercise | -100% | -29,166 | 0 | 20 Jan 2026 | Direct | ||
| Geno J. Germano | DTIL | Common Stock | Purchase | 14.4% | $14,160 | $4.72 | 3,000 | 23,883 | 16 Dec 2025 | Direct |
| Stanley R. Frankel | DTIL | Common Stock | Purchase | 16.1% | $12,690 | $4.70 | 2,700 | 19,478 | 16 Dec 2025 | Direct |
| Melinda Brown | DTIL | Common Stock | Purchase | 6.29% | $6,864 | $4.97 | 1,381 | 23,346 | 15 Dec 2025 | Direct |
| John Alexander Kelly | DTIL | Common Stock | Sale | -1.66% | $8,456 | $6.49 | -1,303 | 77,298 | 03 Nov 2025 | Direct |
| Dario Scimeca | DTIL | Common Stock | Sale | -2.3% | $4,316 | $6.49 | -665 | 28,258 | 03 Nov 2025 | Direct |
| Michael Amoroso | DTIL | Common Stock | Sale | -2.87% | $22,124 | $6.49 | -3,409 | 115,575 | 03 Nov 2025 | Direct |
| Michael Amoroso | DTIL | Restricted Stock Units | Options Exercise | -100% | -9,444 | 0 | 03 Nov 2025 | Direct | ||
| John Alexander Kelly | DTIL | Common Stock | Options Exercise | 4.81% | 3,605 | 78,601 | 02 Nov 2025 | Direct | ||
| John Alexander Kelly | DTIL | Restricted Stock Units | Options Exercise | -100% | -3,605 | 0 | 02 Nov 2025 | Direct | ||
| Dario Scimeca | DTIL | Common Stock | Options Exercise | 6.77% | 1,835 | 28,923 | 02 Nov 2025 | Direct | ||
| Dario Scimeca | DTIL | Restricted Stock Units | Options Exercise | -100% | -1,835 | 0 | 02 Nov 2025 | Direct | ||
| Michael Amoroso | DTIL | Common Stock | Options Exercise | 8.62% | 9,444 | 118,984 | 02 Nov 2025 | Direct | ||
| Stanley R. Frankel | DTIL | Common Stock | Purchase | 19.2% | $13,419 | $4.97 | 2,700 | 16,778 | 26 Sep 2025 | Direct |
| Melinda Brown | DTIL | Common Stock | Purchase | 6.81% | $6,846 | $4.89 | 1,400 | 21,965 | 22 Sep 2025 | Direct |
| John Alexander Kelly | DTIL | Common Stock | Sale | -16.8% | $63,163 | $4.26 | -14,827 | 73,485 | 03 Jul 2025 | Direct |
| Melinda Brown | DTIL | Common Stock | Purchase | 8.91% | $6,963 | $4.14 | 1,682 | 20,565 | 25 Jun 2025 | Direct |
| Kevin Buehler | DTIL | Common Stock | Purchase | 22% | $21,116 | $4.16 | 5,076 | 28,137 | 25 Jun 2025 | Direct |
| Geno J. Germano | DTIL | Restricted Stock Units | Award | 21,000 | 21,000 | 03 Jun 2025 | Direct | |||
| Shari Lisa Pire | DTIL | Restricted Stock Units | Award | 21,000 | 21,000 | 03 Jun 2025 | Direct | |||
| Stanley R. Frankel | DTIL | Restricted Stock Units | Award | 21,000 | 21,000 | 03 Jun 2025 | Direct | |||
| Kevin Buehler | DTIL | Restricted Stock Units | Award | 21,000 | 21,000 | 03 Jun 2025 | Direct | |||
| Melinda Brown | DTIL | Restricted Stock Units | Award | 21,000 | 21,000 | 03 Jun 2025 | Direct | |||
| J. Jefferson Smith | DTIL | Restricted Stock Units | Award | 50,000 | 50,000 | 02 Jun 2025 | Direct | |||
| Dario Scimeca | DTIL | Restricted Stock Units | Award | 50,000 | 50,000 | 02 Jun 2025 | Direct | |||
| Michael Amoroso | DTIL | Restricted Stock Units | Award | 203,390 | 203,390 | 02 Jun 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.